Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRAS mutations are prevalent in various cancers, including colorectal, lung, and pancreatic carcinomas.
• Targeting KRAS directly has been a significant challenge in cancer therapy.
• Proteolysis Targeting Chimeras (PROTACs) represent a new class of bifunctional molecules designed for targeted protein degradation.

Purpose of the Study:

• To review the current landscape of PROTACs targeting KRAS mutations in cancer.
• To highlight key findings, existing limitations, and future directions in this therapeutic area.
• To explore the potential of PROTACs in overcoming traditional KRAS inhibition challenges.

Main Methods:

• Literature search conducted across Medline, Embase, Science Direct, and Scopus databases.
• Keywords used included "PROTACs, protein degradation, anti-tumor action, cancer treatment, KRAS mutation".
• Information supplemented with relevant textbooks, reviews, and documents.

Main Results:

• PROTAC treatment effectively suppresses KRAS-associated downstream signaling pathways, including MAPK and PI3K/AKT.
• Preclinical animal studies demonstrate PROTACs' efficacy in targeting KRAS-mutant tumors.
• PROTACs show potential for inhibiting tumor growth with minimal observed toxicities.

Conclusions:

• PROTACs provide a promising strategy for targeting KRAS mutations, offering an alternative to traditional inhibition.
• Further advancements in PROTAC technology could lead to novel, targeted cancer treatments.
• This approach holds potential for developing specific therapies for KRAS-mutant tumors.